Abstract:Radiation therapy is a commonly applied initial definitive treatment for prostate cancer. Prostate Specific Membrane Antigen (PSMA) is overexpressed in prostate cancer cells and is used as an effective diagnostic and therapeutic target. Targeting prostate cancer with anti-PSMA nanoparticles is a promising methodology, with the potential to minimize the side effects and toxicity of anticancer drugs. The objective of this study is to evaluate the radiobiological effects of PSMA-targeted gold nanoparticles (GNPs) as a theranostic tool for prostate cancer imaging and radiosensitization. The preparation of PSMA-targeted GNPs (PSMA-GNPs) was performed by covalently conjugating anti-PSMA monoclonal antibodies to 15 nm diameter GNPs. The number of GNPs that bind to PSMA positive prostate cancer cells were imaged and quantified by dark-field microscopy. The number of radiation-induced damage foci per cell were quantified by immunofluorescent staining for γ-H2AX. The ability of prostate cancer cells to grow into colonies was measured by colony formation assay. Prostate tumor xenograft models were propagated by the injection of prostate cancer cell lines orthotopically into immunodeficient mice. Mouse tumor xenografts were monitored by multimodality tumor imaging, including X-ray fluorescence (XRF), cone beam computed tomography (CBCT), and bioluminescence tomography. By dark-field microscopy, we found that PSMA-GNPs preferentially bind to PSMA positive LNCaP cells over PSMA negative PC3 cells. In PSMA positive LNCaP cells, we observed a 30% increase in DNA double strand breaks, as quantified by γ-H2AX foci number when PSMA-GNPs were added to radiotherapy (RT, single fraction 5 Gy), compared to RT plus control IgG nanoparticles. However, we did not observe that PSMA-GNPs enhanced DNA damage in PSMA negative PC3 cells. We also found a reduction in LNCaP colony formation by when PSMA-GNPs were added to RT. However, we did not observe radiosensitization in PSMA negative PC3 cells. In the tumor xenograft models, we found that PSMA-GNPs preferentially accumulate in PSMA positive LNCaP tumor xenografts by X-ray fluorescence. PSMA targeted GNPs have a highly specific binding efficiency to PSMA positive prostate cancer cells, which through X-ray fluorescence tomography may be used for the identification of tumor spatial distribution and quantification of nanoparticle binding. The addition of PSMA-GNPs to RT resulted in increased double strand breaks, cell death and inhibition of tumor growth. PSMA-GNPs are novel theranostic tools for tumor imaging and radiosensitization.

Binary Proton Therapy of Ehrlich Carcinoma Using Targeted Gold Nanoparticles

Radiosensitization Effect of Gold Nanoparticles in Proton Therapy

Tumor microenvironment-responsive multifunctional peptide coated ultrasmall gold nanoparticles and their application in cancer radiotherapy.

Beam Energy Considerations for Gold Nano-Particle Enhanced Radiation Treatment

Gold Nanoparticles Permit In Situ Absorbed Dose Evaluation in Boron Neutron Capture Therapy for Malignant Tumors

Polymer‐Protected Gold Nanoparticles for Photothermal Treatment of Ehrlich Adenocarcinoma: In Vitro and In Vivo Studies

Application of Gold Nanoparticles for Improvement of Electroporation-Assisted Drug Delivery and Bleomycin Electrochemotherapy

Gold Nanoparticles as Boron Carriers for Boron Neutron Capture Therapy: Synthesis, Radiolabelling and In vivo Evaluation

Evaluation of PSMA-Targeted Theranostic Gold Nanoparticles for Prostate Cancer Imaging and Radiosensitization

Engineering Radiocatalytic Nanoliposomes with Hydrophobic Gold Nanoclusters for Radiotherapy Enhancement

Au-Pt Nanoparticle Formulation as a Radiosensitizer for Radiotherapy with Dual Effects

Peptide-functionalized gold nanoparticles for boron neutron capture therapy with the potential to use in Glioblastoma treatment

Enhancing Proton Therapy Efficacy Through Nanoparticle-Mediated Radiosensitization

Boron Nanoparticle-Enhanced Proton Therapy: Molecular Mechanisms of Tumor Cell Sensitization

Precise Construction of Dual-Promising Anticancer Drugs Associated with Gold Nanomaterials on Glioma Cancer Cells

Synergetic enhancing effects between platinum nano-sensitizers and clinically approved stabilizing ligands in proton therapy, causing high-yield double-strand breaks of plasmid DNA at relevant dose

Reversibly Extracellular Ph Controlled Cellular Uptake and Photothermal Therapy by PEGylated Mixed-Charge Gold Nanostars.

Size-dependent radiosensitization of PEG-coated gold nanoparticles for cancer radiation therapy

Neuropilin-1-targeted gold nanoparticles enhance therapeutic efficacy of platinum(IV) drug for prostate cancer treatment.

Cell‐Derived Biogenetic Gold Nanoparticles for Sensitizing Radiotherapy and Boosting Immune Response against Cancer

Application of High-Z Gold Nanoparticles in Targeted Cancer Radiotherapy—Pharmacokinetic Modeling, Monte Carlo Simulation and Radiobiological Effect Modeling